CASICASI Pharmaceuticals Inc (NASDAQ:CASI) Historically, October is always a great month for a trend reversal on this name. I think we could see a strong reversal over the coming wks.
CASI
CASICASI Pharmaceuticals, Inc. (CASI) is still in bottoming mode. The technical indicators are looking better now for the stock. The MACD is starting to rise, confirming a bullish divergence has taken form and the Stochastic also has a bullish crossover. It might attempt to breakout above the $1.25 level on Monday and if it succeeds we should expect a strong move to the upside. It has the potential to make another big run next week, so keep a close eye on CASI and don’t miss the trade. The price target of the two Wall Street analysts that rated the stock since the last quarterly report is $3.9
CASICASI Pharmaceuticals Inc (NASDAQ:CASI) The daily chart is shaping up and I expect the next point of resistance to be at $2.25. At some point CASI will take off and never look back. I think that day will come soon and those buying at these prices will be thanking me down the road. Oppenheimer analyst Leland Gershell recently raised the price target on CASI to $6.00 (from $5.00) while maintaining Outperform rating and the CEO purchased 480000 shares in August owning more than 5 million shares. I think CASI is heading higher from here and will make an excellent trade going forward.
CASIThursday's earnings report news has lit a fire under CASI Pharmaceuticals (NASDAQ: CASI) and I don't think it will be put out anytime soon. This looks like the start of a prolonged rally, one that could see this stock trading +400% higher than current levels according to Oppenheimer analyst Leland Gershell that yesterday raised the price target on CASI to $6.00 (from $5.00) while maintaining Outperform rating. From a technical perspective, the stock broke the long-term downtrend line yesterday with some volume if it can stay above this downtrend resistance level, next possible upside resistance may be around the 1.80 level. CASI remains, in my view, undervalued, and based upon recent actions by the company, I think the stock price should head higher. The way to make money in these markets is to find the undervalued stock before the market does. Let's keep an eye on her.
CASI - Long SetupStrong buying from COB/CEO in March at $2.06 and strong buying last year as well from same insider. Break 1.78, Stop signal 1.47. First target 2.33, Second target Momentum.
CASICASI Pharmaceuticals Inc (NASDAQ:CASI) moved up about 9.22% on strong volume last week and it looks like a lot of traders booked gains from the upwards run, but I did exactly the opposite. With the resistance level already identified on the charts and with the huge insider activity revealed, I used the pullback to take a big long position. Usually when insiders buy shares, especially in large amounts it is a sign that positive things are coming. If CASI can keep going up and break the resistance at 2.50 this could further confirm the uptrend and would give a measured move target of nearly 3.25
High Traffic Pivots on CASI ChartCASI saw a nice bump in after-hours trading Friday. Shares hit $1.88. Can the Oppenheimer analyst rating be enough of a catalyst to carry through this momentum into the week ahead is the biggest question. Great volume on Friday but is it all for nothing?
"What had sparked some excitement came in light of new analyst activity. Oppenheimer analyst Leland Gershell initiated coverage on CASI. The analyst gave it an Outperform rating and announced a price target of $5. That represents a 182% premium to Friday’s closing price for CASI stock."
Original Quote Source: 5 Biotech Penny Stocks To Watch With Recent & Upcoming Events
Invest IDEA CASI openinsider. com/search?q=CASI
insider BUY
CASI Zhang Larry Pres P - Purchase $1.90 +20,153 20,153 New +$38,291
CASI He Wei-Wu COB, CEO, 10% P - Purchase $1.90 +4,152,426 12,809,942 +48% +$7,889,609
CASI Pharmaceuticals Inc (CASI) Yahoo finance “CASI Pharmaceuticals Inc (CASI), a biopharmaceutical company dedicated to developing high-quality products and therapeutics to the global health market, announced earlier this month that it had received National Medical Products Administration approval of Melphalan Hydrochloride For Injection.
CASI Pharmaceuticals Executive Chairman Wei-Wu He, Ph.D., commented, ''NMPA approval of Melphalan Hydrochloride For Injection (EVOMELA®) is encouraging news for patients in China with multiple myeloma as there is no commercially available melphalan formulation in the country. EVOMELA's approval, therefore, addresses a significant unmet medical need. In addition, EVOMELA®‘s proprietary formulation of melphalan, a first-line therapy for multiple myeloma patients, offers considerable clinical advantages as it does not contain propylene glycol, which may cause side effects, it has long stability when reconstituted for infusion, and is the only intravenous melphalan product approved for use in the high-dose conditioning indication in pre-transplant therapy.''
This is one I feel has great growth potential. Good thing as well at there is more institutional investors than general public shows investors have a lot of confidence in the company.
Again, I’m not giving financial advice and you should check things out for yourself. Just sharing my thoughts
CASI: Holy Grail buy on the weeklyMarket retreats to 20 period EMA after making new highs (for long positions)/lows (for shorts) with ADX (14period) >30. Some people use the 20 period SMA . Projection is a retest of the highs. Trailing stop. ***Failed grails tend to move (painfully) in the opposite direction.
Setup invalid below weekly EMA (5.73)
CASI TIME TO SHORTCASI TIME TO SHORT. It is hitting the red resistance line. Once it hits back the green line we can go long.
CASI: ONE MORE TEST OF THE LOW BEFORE A POSSIBLE WAVE UP?CASI has broken the last upward move, so it's possible to see more downside, with a potential test on the previous low. Finished this retrace i'm expecting a strong wave up.
